John Leichner, MD
Surgery · Philadelphia, PANPI 1225072192
Payments from drug & device makers
Across 48 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$214
- Otsuka America Pharmaceutical, Inc.$147
- Indivior Inc.$129
- Johnson & Johnson$122
- Novo Nordisk$80
- AbbVie$49
- plus $215 from 11 others
What the payments were for
- Food & beverage$955100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 10 | $214 |
| Otsuka America Pharmaceutical, Inc. | 6 | $147 |
| Indivior Inc. | 6 | $129 |
| Johnson & Johnson | 7 | $122 |
| Novo Nordisk | 4 | $80 |
| AbbVie | 3 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 1 | $28 |
| Luye Pharma (USA) Ltd. | 1 | $25 |
| Bayer | 1 | $19 |
| Noven Therapeutics, LLC | 1 | $19 |
| Pfizer | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$955 in reported general payments places this provider in the 45th percentile of 1,424 surgery providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,767 |
| Ranolazine ErRanolazine | 12 | $478 |
| Metoprolol Succinate | 43 | $374 |
| Lisinopril | 46 | $284 |
| Atorvastatin Calcium | 28 | $274 |
| Alprazolam | 21 | $252 |
| ClopidogrelClopidogrel Bisulfate | 19 | $240 |
| Tamsulosin Hcl | 21 | $226 |
| Atenolol | 19 | $191 |
| Cilostazol | 15 | $186 |
| Ropinirole Hcl | 12 | $184 |
| Montelukast Sodium | 17 | $176 |
| Pantoprazole Sodium | 17 | $174 |
| Amlodipine Besylate | 40 | $164 |
| Lovastatin | 12 | $148 |
Paid to pharmacies, not to this prescriber.
Other surgery in Philadelphia
- Giorgos KarakousisPhiladelphia$8.8M
- James MarkmannPhiladelphia$1.8M
- John MiuraPhiladelphia$1.3M
- Olwadamilola FayanjuPhiladelphia$668K
- Julia TchouPhiladelphia$555K
- Ali NajiPhiladelphia$539K
- Ashesh ShahPhiladelphia$328K
- Lisa RaePhiladelphia$318K
- Hooman YarmohammadiPhiladelphia$304K
- Arminder JassarPhiladelphia$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.